trans-Cadina-1(6),4-diene is a low-profile sesquiterpene hydrocarbon that appears repeatedly in GC-MS profiles of manuka and other woody or spice-like aromatic materials. The strongest live evidence found here is identity, registry, and occurrence data; standalone biological evidence is sparse and mostly computational or mixture-level. For AromaForge, it is most accurate to frame this constituent as a compositional marker with limited early mechanistic hypotheses and explicit evidence gaps.
Chemical identity and composition
NIST lists trans-Cadina-1(6),4-diene with formula C15H24, InChIKey ULTBCADWJVQRCF-OLZOCXBDSA-N, and CAS 20085-11-4. NIST also notes closely related naming overlap with Calamenen-3,5(10)-diene and other stereoisomer labels. In the local archive, manuka lists this constituent at 4.35% in a 2024 GC-MS batch report.
Aroma and practical use
- Use the recorded woody, dry, resinous, terpenic, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2024 manuka GC-MS batch report measured trans-Cadina-1(6),4-diene at 4.35%, supporting its role as a notable supporting sesquiterpene in at least some manuka chemotypes.
A 2024 manuka GC-MS batch report measured trans-Cadina-1(6),4-diene at 4.35%, supporting its role as a notable supporting sesquiterpene in at least some manuka chemotypes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2023 HPTLC and GC-MS study of selected Melaleuca oils identified trans-Cadina-1(6),4-diene as one of the variables contributing strongly to multivariate separation of oil types, supporting chemotaxonomic relevance rather than direct pharmacology.
A 2023 HPTLC and GC-MS study of selected Melaleuca oils identified trans-Cadina-1(6),4-diene as one of the variables contributing strongly to multivariate separation of oil types, supporting chemotaxonomic relevance rather than direct pharmacology.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 cedar wood tar paper reported that trans-Cadina-1(6),4-diene was among the top-scoring docked terpenoids for LasR and DNA-gyrase related targets, with favorable MM/GBSA and molecular-dynamics stability metrics, but these are computational predictions only.
A 2025 cedar wood tar paper reported that trans-Cadina-1(6),4-diene was among the top-scoring docked terpenoids for LasR and DNA-gyrase related targets, with favorable MM/GBSA and molecular-dynamics stability metrics, but these are computational predictions only.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Screening assumption (family fallback). It is not a verified constituent-specific exposure limit.
model fallback · Essential Oil Safety and Dermal Limits — sesquiterpenes generally do not have safety concerns; beta-caryophyllene RIFM fragrance material safety dataThe Good Scents Company page reviewed in this pass listed trans-cadina-1(6),4-diene as not for fragrance use and not for flavor use, but did not provide a primary regulatory rationale or exposure limit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No constituent-specific IFRA dermal limit, human tolerability study, or phototoxicity warning for isolated trans-Cadina-1(6),4-diene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The only safety-like quantitative data located were in silico acute-toxicity predictions, which should not be presented as established toxicology.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
quorum sensing target hypothesis
A 2025 wood-tar docking and simulation paper proposed favorable binding of trans-Cadina-1(6),4-diene to the LasR quorum-sensing receptor, but this remains a computational hypothesis rather than a validated biological mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical study specific to isolated trans-Cadina-1(6),4-diene was verified in this pass.
- No purified-constituent in vitro or in vivo bioactivity paper with direct dose-response testing was located in the accessible source set.
- Constituent-specific dermal, inhalation, and repeated-dose safety data for isolated trans-Cadina-1(6),4-diene were not located.
- Second pass (2026-07-13): no IFRA Standard or RIFM assessment for CAS 20085-11-4 was located. The Good Scents Company page for this exact CAS ('7aH,10bH-cadina-1(6),4-diene', 20085-11-4) shows 'None found' GHS classification and 'not determined' oral/dermal/inhalation toxicity, with usage 'not for fragrance use' / 'not for flavor use'. The prior dermal_limit_pct 25 and sensitizing:true had no citation in this record's sources[] and are corrected to null pending real data.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.